(Q37471532)

20 August 2017

1 reference

title

Cardiac toxicity with anti-HER-2 therapies: what have we learned so far? (English)

1 reference

20 August 2017

0 references

Martine Piccart-Gebhart

4

object named as

Martine Piccart-Gebhart

0 references

Evandro de Azambuja

1

object named as

Evandro de Azambuja

0 references

Philippe L. Bedard

object named as

Philippe L Bedard

2

0 references

author name string

Thomas Suter

3

1 reference

20 August 2017

publication date

1 April 2009

1 reference

20 August 2017

1 reference

20 August 2017

volume

4

1 reference

20 August 2017

issue

2

1 reference

20 August 2017

page(s)

77-88

1 reference

https://scigraph.springernature.com/pub.10.1007/s11523-009-0112-2

20 August 2017

exact match

0 references

cites work

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

1 reference

12 December 2020

Pathophysiology and diagnosis of cancer drug induced cardiomyopathy.

1 reference

12 December 2020

Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cells

1 reference

12 December 2020

Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity

1 reference

12 December 2020

Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials

1 reference

12 December 2020

Cardiotoxicity of trastuzumab in clinical practice

1 reference

12 December 2020

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

12 December 2020

Neuregulins regulate cardiac parasympathetic activity: muscarinic modulation of beta-adrenergic activity in myocytes from mice with neuregulin-1 gene deletion

1 reference

12 December 2020

Cardiac dysfunction in the trastuzumab clinical trials experience

1 reference

12 December 2020

Neuregulin-1 beta attenuates doxorubicin-induced alterations of excitation-contraction coupling and reduces oxidative stress in adult rat cardiomyocytes

1 reference

12 December 2020

Heart-valve mesenchyme formation is dependent on hyaluronan-augmented activation of ErbB2-ErbB3 receptors

1 reference

12 December 2020

Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized

1 reference

12 December 2020

Letter Regarding Article by Okoshi et al, “Neuregulins Regulate Cardiac Parasympathetic Activity: Muscarinic Modulation of β-Adrenergic Activity in Myocytes From Mice With Neuregulin-1 Gene Deletion”

1 reference

12 December 2020

Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes

1 reference

12 December 2020

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

12 December 2020

Congestive Heart Failure in Older Women Treated With Adjuvant Anthracycline Chemotherapy for Breast Cancer

1 reference

12 December 2020

ErbB2 is essential in the prevention of dilated cardiomyopathy.

1 reference

12 December 2020

Cardiotoxicity profile of trastuzumab

1 reference

12 December 2020

Requirement for neuregulin receptor erbB2 in neural and cardiac development

1 reference

12 December 2020

Jumping higher: is it still possible? The ALTTO trial challenge

1 reference

12 December 2020

Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Bre

1 reference

12 December 2020

Herceptin and the heart--a molecular modifier of cardiac failure

1 reference

12 December 2020

The new generation of breast cancer clinical trials: the right drug for the right target

1 reference

12 December 2020

Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial.

1 reference

12 December 2020

Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment

1 reference

12 December 2020

ErbB3 is required for normal cerebellar and cardiac development: a comparison with ErbB2-and heregulin-deficient mice

1 reference

12 December 2020

Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer

1 reference

12 December 2020

Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas

1 reference

12 December 2020

Continuation of trastuzumab beyond disease progression

1 reference

12 December 2020

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

12 December 2020

Neuregulin-1 induces a negative inotropic effect in cardiac muscle: role of nitric oxide synthase

1 reference

12 December 2020

Role of neuregulin-1/ErbB signaling in cardiovascular physiology and disease: implications for therapy of heart failure

1 reference

12 December 2020

Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity

1 reference

12 December 2020

Trastuzumab and breast cancer

1 reference

12 December 2020

Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition

1 reference

12 December 2020

Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells

1 reference

12 December 2020

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

1 reference

12 December 2020

Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial

1 reference

12 December 2020

10.1007/S11523-009-0112-2

Identifiers

DOI

1 reference

20 August 2017

1 reference